CEL-SCI Corporation
June 22, 2026
Theater 2
Type: Company Presentation
Focus Area:
Oncology
CEL-SCI Corporation is a Phase 3 biotechnology company that has shown that boosting a cancer patient’s immune system before surgery, can improve overall survival. Based on Phase 3 results we are pursuing permission to sell its cancer drug Multikine outside of the US, expected in 2026.
In the US we are pursuing final approval of Multikine by conducting a 212-patient confirmatory study. In our Phase 3 head and neck cancer study we showed a 46-month survival benefit in patients who were treated with our Multikine followed by surgery and radiotherapy, but in the group that had chemotherapy added we had no survival benefit.
In the target population for the confirmatory study, Multikine significantly extended survival demonstrating a 73% survival rate with Multikine vs. 45% without at 5 years post treatment (p=0.0015). The Hazard Ratio for this population is 0.35 with an upper limit of 0.66. We have operations in Vienna, VA and Baltimore, MD.
Company HQ City:
Vienna
Company HQ State:
Virginia
Company HQ Country:
United States
Year Founded:
1983
Lead Product in Development:
Multikine (Leukocyte Interleukin, Injection)
CEO
Geert Kersten
Development Phase of Lead Product
Phase III
Number of Unlicensed Products Looking for Licensing
one
Exchange
NYSE American
Ticker
CVM
When you expect your next catalyst update?
2026
What is your next catalyst (value inflection) update?
Potential sales outside of the US
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}